glp 1 drugs wikipedia Trends in the Development of GLP-1 Receptor Agonists Oral Small-Molecule GLP-1 Receptor Agonists:

The peptide downregulates or inhibits key lipogenic enzymes including fatty acid synthase and acetyl-CoA carboxylase, which are responsible for converting excess dietary carbohydrates and other substrates into fatty acids for storage

Some individuals also have black spots on the dorsal side of their abdomens and legs

10.1007/s40200-018-00382-y J

Khoo J, Hsiang JC, Taneja R et al (2019) Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease

The peptide has the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, incorporating a lactam bridge that enhances metabolic stability and receptor selectivity

One honest sentence on evidence, up front: there is no registered human clinical trial of the GLOW blend itself